๐ฐ Advanced Solid Tumors News
Page 3 - Advanced Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advanced Solid Tumors. Real-time updates on events, politics, business and more.
August 23, 2023
Treatment with erdafitinib resulted in clinical benefit for patients with advanced solid tumors harboring susceptible FGFR alterations who had exhausted all other treatment options, meeting the primary end point of overall response rate of the phase 2 RAGNAR trial.
August 10, 2023
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
August 9, 2023
Kedar Kirtane, MD, speaks on the unique mechanism of action of A2B530 and how the agent could represent a huge leap forward in the application of CAR T-cell agents for patients with solid tumors if the EVEREST-1 study proves to be positive.
August 1, 2023
CARLSBAD, Calif., Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large...
July 27, 2023
ENHERTUยฎ has demonstrated clinically meaningful progression-free survival and overall survival in topline results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial. The...
July 25, 2023
Kedar Kirtane, MD, discusses the design of the phase 1/2 EVEREST-1 trial, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with advanced solid tumors.
June 6, 2023
Evaxion Biotech A/S (NASDAQ: EVAX) (โEvaxionโ or the โCompanyโ), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in ...
June 5, 2023
Press Release ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors ... | June 5, 2023
June 5, 2023
AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar... | June 5, 2023
June 4, 2023
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality